BioSpace News Archive

Allarity Therapeutics, Inc. announced the appointment of Roberto Pili, M.D., as a member of the Company’s Scientific Advisory Board.

ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract entitled ‘Therapeutic vaccination with CLB-3000 in a mouse model of chronic Hepatitis B induces anti-HBs responses associated with functional cure’ was accepted for poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2022.

Novozymes, the leading biotech powerhouse, and AgroFresh, a global leader in post-harvest freshness solutions, are forming a research and commercialization partnership towards developing biological solutions that can improve post-harvest food quality and minimize waste by fighting fungal pathogens.

The American Association for Clinical Chemistry announced Wednesday that they have selected Visby Medical as a finalist for the 2022 Disruptive Technology Award for its handheld point-of-care PCR diagnostic technology.

Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Synergy Innovation Co., Ltd, to purchase its majority stake (approximately 64 percent) of M.I.Tech Co., Ltd, (“M.I.Tech”).

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (the " Company "), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, announces that it is extending the expiry date (the “ Warrant Extension ”) and amending the exercise price (the “ Amended Exercise Price ”) of 3,117,957 common share purchase warrants (“ Warrants ”) of the Company.

Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“ Aleafia Health ” or the “ Company ”) will announce on June 23 prior to market open its fifth quarter and fiscal year results for the period ending March 31, 2022.

Biogen Inc. will present new data from clinical studies aimed at assessing remaining unmet needs for people living with spinal muscular atrophy and evaluating the potential impact of SPINRAZA® in different patient populations at the SMA Research & Clinical Care Meeting hosted by Cure SMA this week in Anaheim, Calif.

Oyster Point Pharma, Inc. announced that a scientific poster featuring data from pivotal clinical trials of TYRVAYA® Nasal Spray has been selected for the Top 5 Poster Session at the American Optometric Association’s Optometry’s Meeting® being held on June 15-18 in Chicago, Illinois.

Hepion Pharmaceuticals, Inc. announced that five abstracts have been accepted for poster presentations at the European Association for the Study of the Liver International Liver Congress™ 2022 taking place June 22 – 26, 2022 in London, UK and digitally.